Panagora Asset Management Inc. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 38.6% in the fourth quarter, HoldingsChannel reports. The fund owned 47,685 shares of the biopharmaceutical company’s stock after selling 29,988 shares during the period. Panagora Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $36,807,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in REGN. WPG Advisers LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the last quarter. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $31,000. Entrust Financial LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $32,000. Caitlin John LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $34,000. Finally, MCF Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 15 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on REGN shares. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $900.00 to $700.00 in a report on Monday, May 18th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $792.65.
Regeneron Pharmaceuticals Stock Up 0.5%
Shares of Regeneron Pharmaceuticals stock opened at $614.98 on Tuesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $689.17 and its two-hundred day simple moving average is $736.78. The company has a market cap of $65.02 billion, a P/E ratio of 14.98, a PEG ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 12-month low of $503.25 and a 12-month high of $821.11.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $8.22 EPS. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.
Insider Buying and Selling at Regeneron Pharmaceuticals
In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
